Abstract
A 47-year-old man with chronic plaque psoriasis and type II diabetes mellitus on ustekinumab 45mg 12 weekly injections, his first biologic therapy, was switched to adalimumab 40mg alternate weeks (10/02/2020) when his Psoriasis Area and Severity Index (PASI) was 11.4 due to loss of effectiveness. Due to the COVID-19 outbreak, the U.K Prime Minister advised clinically vulnerable people, including people on immunosuppressive medication with comorbidities including diabetes, to stay home avoiding face-to-face contact (23/03/2020). We performed a Critically Appraised Topic review to understand whether it was possible to remotely assess his response to adalimumab with AI assistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
